RxDoctor Payments Data

Karin Maddox, MD

Neurology · Panama City, FLNPI 1780644997

Payments from drug & device makers

$7,213in general payments, 2019–2025

Across 395 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$639
  • Novartis$503
  • Amgen$376
  • UCB, Inc.$359
  • Jazz Pharmaceuticals Inc.$353
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$7,213100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,213 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$245,569
Medicare patients
621
Services billed
2,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5038$502,058
Avonex Pen (4 Pack)Interferon Beta-1a12$96,770
UbrelvyUbrogepant13$36,795
QuliptaAtogepant32$35,314
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,239$34,762
BriviactBrivaracetam16$32,943
Nurtec OdtRimegepant Sulfate16$31,340
Aimovig AutoinjectorErenumab-Aooe39$30,795
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen685$24,793
Glatiramer Acetate13$22,412
BelsomraSuvorexant27$14,902
Lacosamide55$9,249
Fentanyl91$8,689
Xtampza ErOxycodone Myristate15$8,000
Levetiracetam188$6,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$97$502,05838 claims
AbbVieUbrelvy, Qulipta$1,150$72,10945 claims
UCB, Inc.Briviact$359$32,94316 claims
PfizerNurtec Odt$639$31,34016 claims
MerckBelsomra$117$14,90227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.

Other neurology in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →